Introduction: Denosumab, a monoclonal antibody, was recently approved by US Food and Drug Administration for treatment of postmenopausal osteoporosis and cancer skeletal related events (SRE). A variable incidence of hypocalcemia (5.5-13%) has been reported with denosumab as compared to the commonly used bisphosphonate, zolendronic acid (3.4-6%).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.